Praesidian Capital Acquires Undisclosed Genetics Business

Praesidian Capital Acquires Leading Testing Business

August 26, 2021

Industrial Services

Praesidian Capital, a New York–based private equity firm, acquired a controlling interest in a leading materials/testing services business that serves energy, aerospace & defense, laboratory, steel & pipe and other industrial markets. Praesidian said it will partner with management to scale the business organically and through strategic acquisitions to expand capabilities and market share.

Praesidian Capital Acquires Undisclosed Southwestern E‑commerce Distributor

April 12, 2022

Logistics & Distribution

Praesidian Capital acquired a controlling interest in a leading e‑commerce distribution business located in the Southwestern United States. Spirit Bank of Tulsa provided financing for the transaction and Ice Miller LLP served as legal counsel to Praesidian; the firm said the deal expands its e‑commerce activity and footprint in the Southwest.

Exact Sciences Acquires PreventionGenetics

January 9, 2022

Healthcare Services

Exact Sciences Corp. acquired PreventionGenetics, a CLIA- and ISO-accredited genetic testing laboratory based in Marshfield, Wisconsin, for $190 million (50% stock, 50% cash) to accelerate its entrance into hereditary cancer testing. PreventionGenetics reported preliminary 2021 revenue of about $36 million and ~100+ staff; Exact Sciences intends to leverage its commercial reach to expand hereditary cancer and genetic testing domestically and internationally.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

Praesidian Capital Announces Exit of E-commerce Distribution Business

August 6, 2025

E-Commerce

Praesidian Capital announced the successful exit of its tech-enabled e-commerce consumer products distribution business. The firm did not disclose the buyer, target company name, or transaction financials in the announcement and said it was pleased to realize the investment and thanked the management team.

Isracann Biosciences to Acquire Praesidio Health

February 23, 2022

Biotechnology

Isracann Biosciences Inc. entered into a binding letter of intent to acquire Canadian medical research company Praesidio Health Inc. under a stock transaction valued at approximately CAD 4.0 million. Praesidio develops and validates evidence-based natural health medicines (including formulations with cannabinoids and/or psilocybin) for conditions such as urological disorders, anxiety/stress, immune support and sleep.